Related Experiment Video
Updated: Sep 21, 2025
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
Published on: May 26, 2023
Bivalirudin in pediatric extracorporeal membrane oxygenation
Lindsay M Ryerson1, Ali B V McMichael2
1University of Alberta, Edmonton, Alberta, Canada.
Insights
Bivalirudin shows promise as an anticoagulant for pediatric extracorporeal membrane oxygenation (ECMO) patients who did not respond to unfractionated heparin. Further studies are needed to confirm its safety and effectiveness.
Area of Science:
- Pediatric critical care medicine
- Cardiovascular research
- Pharmacology
Background:
- Extracorporeal membrane oxygenation (ECMO) requires anticoagulation.
- Unfractionated heparin (UFH) is the standard anticoagulant but can fail.
- Alternative anticoagulants are needed for pediatric ECMO patients.
Purpose of the Study:
- To review the current literature on bivalirudin as an alternative anticoagulant in pediatric ECMO.
- To evaluate the safety, efficacy, and monitoring of bivalirudin in this population.
Main Methods:
- Literature review of studies on bivalirudin in pediatric ECMO.
- Analysis of clinical outcomes, transfusion rates, and costs.
- Assessment of laboratory monitoring methods for bivalirudin.
Main Results:
- Bivalirudin may reduce blood product transfusions and costs compared to UFH.
- Clinical outcomes appear similar between bivalirudin and UFH in some studies.
- Activated partial thromboplastin time (aPTT) monitoring has limitations; dilute thrombin time (dTT) and viscoelastic assays show promise.
Conclusions:
- Bivalirudin is a potentially effective and well-tolerated alternative anticoagulant for pediatric ECMO patients who have failed UFH.
- Prospective, multicenter studies are essential to confirm the safety and efficacy of bivalirudin.
- Further research is needed to optimize bivalirudin monitoring in pediatric ECMO.
Purpose Of Review:
This review summarizes the current literature surrounding the use of bivalirudin as an alternative anticoagulant for pediatric extracorporeal membrane oxygenation (ECMO) patients.
Recent Findings:
Recent single center studies describe that bivalirudin may be associated with decreased blood product transfusion, decreased cost and similar clinical outcomes for pediatric ECMO patients who have failed unfractionated heparin (UFH) anticoagulation. aPTT is the most common test to monitor bivalirudin but has several limitations. Other tests including dilute thrombin time (dTT) and viscoelastic assays are promising but more study is needed. Current evidence suggests that bivalirudin is a well tolerated and effective alternative anticoagulant for pediatric ECMO patients who have failed UFH anticoagulation but prospective studies are needed to confirm these results.
Summary:
Bivalirudin is a promising alternative anticoagulant for pediatric ECMO patients who have failed UFH. Large prospective, multicenter studies are needed to confirm safety and efficacy.
